SQZ Biotechnologies

SQZ Biotechnologies EBIT per Share

The EBIT per Share of SQZ Biotechnologies (SQZB) as of Nov 4, 2026 is -2.06 USD. In the previous year, EBIT per Share was -2.74 USD — a change of -24.69% (higher).

EBIT per Share

-2.06USD

YoY

-24.69%

Last updated:

EBIT per Share of SQZ Biotechnologies is 2023 -2.06 USD. EBIT per Share of SQZ Biotechnologies was 2022 -2.74 USD. It decreases by -24.69% higher compared to the previous year.

The SQZ Biotechnologies EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
-2.44 USD
Jan 1, 2022
-2.74 USD
Jan 1, 2023
-2.06 USD
Jan 1, 2024 (e)
-2.26 USD
Jan 1, 2025 (e)
-2.60 USD
Jan 1, 2026 (e)
-4.29 USD
Jan 1, 2027 (e)
-8.37 USD
Jan 1, 2028 (e)
15.98 USD
The SQZ Biotechnologies EBIT per Share history
YEAREBIT per ShareYoY
est15.98USD-290.96%
est-8.37USD+95.23%
est-4.29USD+64.89%
est-2.60USD+15.07%
est-2.26USD+9.61%
-2.06USD-24.69%
-2.74USD+11.92%
-2.44USD+41.19%
-1.73USD+49.01%
-1.16USD+67.93%
-0.69USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SQZ Biotechnologies Stock analysis

What does SQZ Biotechnologies do? SQZ Biotechnologies Co. develops cell therapies for cancer, infectious diseases, and serious conditions through clinical-stage platforms. The company focuses on engineered antigen presentation to activate immune responses, with its SQZ Enhanced APC (eAPC) Platform generating tumor-specific CD8+ T cell activation for antitumor responses. The SQZ Activating Antigen Carrier (AAC) Platform uses red blood cells engineered with tumor antigens and adjuvants to induce in vivo antigen presentation, while the SQZ Tolerizing Antigen Carrier (TAC) Platform aims to establish immune tolerance via antigen-specific in vivo mechanisms. These platforms target oncology applications, with the eAPC and AAC candidates in clinical development. The company's revenue model relies on clinical development and partnerships for its cell therapy platforms. SQZ Biotechnologies Co. is a clinical-stage biotechnology firm, meaning it generates income through research and development funding, potential future licensing agreements, and partnerships with pharmaceutical companies. Its focus on oncology and immune activation positions it for collaboration with biopharma entities seeking to advance cell therapy technologies. The primary buyers of its technology are pharmaceutical companies interested in integrating these platforms into their therapeutic pipelines. SQZ Biotechnologies Co. targets the oncology segment for its cell therapy platforms, specifically focusing on tumor antigen-specific immune activation. The company's platforms are designed for patients with cancer, infectious diseases, and serious conditions, but its clinical-stage development is primarily directed at oncology applications. The SQZ eAPC and AAC platforms are in clinical development, with the company aiming to advance these candidates toward regulatory approval and commercialization. The TAC platform is also under development for immune tolerance applications, though it is not yet in clinical stages. SQZ Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SQZ Biotechnologies stock

EBIT per Share of SQZ Biotechnologies is -2.06 USD in 2023.

EBIT per Share of SQZ Biotechnologies changed from -2.74 USD to -2.06 USD, representing a -24.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share SQZ Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — SQZ Biotechnologies

All Key Metrics — SQZ Biotechnologies